Tissue Regenix Group plc
TRX.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.99 | 1.56 |
| FCF Yield | -0.91% | 0.00% | -2.71% | 2.60% |
| EV / EBITDA | 7,503.12 | 0.00 | 78.52 | 220.15 |
| Quality | ||||
| ROIC | -1.29% | 0.00% | -1.42% | -0.82% |
| Gross Margin | 41.82% | 0.00% | 52.54% | 55.26% |
| Cash Conversion Ratio | 0.22 | – | 4.86 | -2.12 |
| Growth | ||||
| Revenue 3-Year CAGR | 18.21% | 16.40% | 13.29% | 24.19% |
| Free Cash Flow Growth | 0.00% | 100.00% | -229.84% | 190.68% |
| Safety | ||||
| Net Debt / EBITDA | 1,984.80 | 0.00 | 8.46 | 20.32 |
| Interest Coverage | 0.00 | 0.00 | 1.32 | -0.63 |
| Efficiency | ||||
| Inventory Turnover | 0.48 | 0.00 | 0.48 | 0.63 |
| Cash Conversion Cycle | 137.31 | 0.00 | 150.88 | 187.11 |